144 related articles for article (PubMed ID: 26537074)
21. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
22. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
23.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
24. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract][Full Text] [Related]
26. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
27. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract][Full Text] [Related]
28. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
29. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Dalgliesh GL; Furge K; Greenman C; Chen L; Bignell G; Butler A; Davies H; Edkins S; Hardy C; Latimer C; Teague J; Andrews J; Barthorpe S; Beare D; Buck G; Campbell PJ; Forbes S; Jia M; Jones D; Knott H; Kok CY; Lau KW; Leroy C; Lin ML; McBride DJ; Maddison M; Maguire S; McLay K; Menzies A; Mironenko T; Mulderrig L; Mudie L; O'Meara S; Pleasance E; Rajasingham A; Shepherd R; Smith R; Stebbings L; Stephens P; Tang G; Tarpey PS; Turrell K; Dykema KJ; Khoo SK; Petillo D; Wondergem B; Anema J; Kahnoski RJ; Teh BT; Stratton MR; Futreal PA
Nature; 2010 Jan; 463(7279):360-3. PubMed ID: 20054297
[TBL] [Abstract][Full Text] [Related]
30. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
Simon JM; Hacker KE; Singh D; Brannon AR; Parker JS; Weiser M; Ho TH; Kuan PF; Jonasch E; Furey TS; Prins JF; Lieb JD; Rathmell WK; Davis IJ
Genome Res; 2014 Feb; 24(2):241-50. PubMed ID: 24158655
[TBL] [Abstract][Full Text] [Related]
31. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
32. An actin-WHAMM interaction linking SETD2 and autophagy.
Seervai RNH; Grimm SL; Jangid RK; Tripathi DN; Coarfa C; Walker CL
Biochem Biophys Res Commun; 2021 Jun; 558():202-208. PubMed ID: 33036756
[TBL] [Abstract][Full Text] [Related]
33. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.
Santos VE; da Costa WH; Bezerra SM; da Cunha IW; Nobre JQC; Brazão ES; Meduna RR; Rocha MM; Fornazieri L; Zequi SC
Clin Genitourin Cancer; 2021 Aug; 19(4):339-345. PubMed ID: 33839039
[TBL] [Abstract][Full Text] [Related]
35.
Kim SH; Park WS; Chung J
Investig Clin Urol; 2019 May; 60(3):148-155. PubMed ID: 31098421
[TBL] [Abstract][Full Text] [Related]
36. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
[TBL] [Abstract][Full Text] [Related]
37. Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma.
Wang X; Xia Z; Li Z; Zhang C
Medicine (Baltimore); 2022 Aug; 101(31):e29561. PubMed ID: 35945780
[TBL] [Abstract][Full Text] [Related]
38. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract][Full Text] [Related]
39. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
40. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
Mehdi A; Riazalhosseini Y
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
